UBS AM’s Johnson & Johnson JNJ Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$4.8B Buy
19,628,113
+2,352,176
+14% +$548M 1% 12
2025
Q4
$3.58B Buy
17,275,937
+1,376,828
+9% +$272M 0.76% 16
2025
Q3
$2.95B Sell
15,899,109
-3,775,060
-19% -$647M 0.64% 19
2025
Q2
$3.01B Buy
19,674,169
+3,319,402
+20% +$510M 0.61% 22
2025
Q1
$2.71B Buy
16,354,767
+911,461
+6% +$143M 0.69% 19
2024
Q4
$2.23B Sell
15,443,306
-1,132,906
-7% -$176M 0.52% 26
2024
Q3
$2.69B Sell
16,576,212
-1,436,136
-8% -$229M 0.69% 19
2024
Q2
$2.63B Buy
18,012,348
+4,783,784
+36% +$711M 0.76% 16
2024
Q1
$2.09B Sell
13,228,564
-912,112
-6% -$145M 0.74% 22
2023
Q4
$2.22B Buy
14,140,676
+3,037,885
+27% +$466M 0.87% 15
2023
Q3
$1.73B Sell
11,102,791
-106,577
-1% -$17.6M 0.77% 15
2023
Q2
$1.74B Hold
11,209,368
0.84% 13
2023
Q1
$1.74B Buy
11,209,368
+165,097
+1% +$26.7M 0.84% 13
2022
Q4
$1.95B Buy
11,044,271
+598,643
+6% +$103M 1.02% 8
2022
Q3
$1.71B Sell
10,445,628
-29,708
-0.3% -$5.03M 0.96% 9
2022
Q2
$1.86B Sell
10,475,336
-128,050
-1% -$22.8M 0.97% 10
2022
Q1
$1.88B Sell
10,603,386
-362,015
-3% -$61.6M 0.81% 11
2021
Q4
$1.88B Sell
10,965,401
-313,188
-3% -$51.3M 0.72% 15
2021
Q3
$1.82B Buy
11,278,589
+602,259
+6% +$103M 0.75% 17
2021
Q2
$1.76B Buy
10,676,330
+235,054
+2% +$38.9M 0.75% 16
2021
Q1
$1.72B Sell
10,441,276
-89,205
-0.8% -$14.4M 0.76% 18
2020
Q4
$1.66B Buy
10,530,481
+499,411
+5% +$73.7M 0.78% 18
2020
Q3
$1.49B Sell
10,031,070
-675,302
-6% -$99.9M 0.8% 16
2020
Q2
$1.51B Sell
10,706,372
-756,161
-7% -$110M 0.92% 14
2020
Q1
$1.5B Buy
11,462,533
+859,767
+8% +$122M 1.08% 11
2019
Q4
$1.55B Sell
10,602,766
-443,499
-4% -$60.2M 0.95% 12
2019
Q3
$1.43B Sell
11,046,265
-642,264
-5% -$84.6M 0.96% 12
2019
Q2
$1.63B Sell
11,688,529
-1,369,706
-10% -$190M 1.16% 8
2019
Q1
$1.83B Buy
13,058,235
+498,553
+4% +$66.8M 1.35% 6
2018
Q4
$1.62B Buy
12,559,682
+1,100,018
+10% +$153M 1.4% 5
2018
Q3
$1.58B Buy
11,459,664
+21,385
+0.2% +$2.84M 1.18% 8
2018
Q2
$1.39B Sell
11,438,279
-305,795
-3% -$38.2M 1.06% 9
2018
Q1
$1.51B Buy
11,744,074
+1,247,631
+12% +$169M 1.19% 8
2017
Q4
$1.47B Buy
10,496,443
+1,324,868
+14% +$185M 1.24% 7
2017
Q3
$1.19B Sell
9,171,575
-233,936
-2% -$31M 1.09% 8
2017
Q2
$1.24B Sell
9,405,511
-572,704
-6% -$73.1M 1.2% 8
2017
Q1
$1.24B Buy
9,978,215
+150,765
+2% +$18M 1.27% 6
2016
Q4
$1.13B Sell
9,827,450
-1,044,605
-10% -$121M 1.27% 6
2016
Q3
$1.28B Sell
10,872,055
-383,901
-3% -$46.6M 1.38% 6
2016
Q2
$1.37B Buy
11,255,956
+1,633,647
+17% +$186M 1.54% 4
2016
Q1
$1.04B Buy
9,622,309
+335,426
+4% +$34.7M 1.21% 6
2015
Q4
$954M Sell
9,286,883
-894,115
-9% -$89.9M 1.09% 7
2015
Q3
$950M Sell
10,180,998
-704,115
-6% -$68.1M 1.05% 7
2015
Q2
$1.06B Buy
10,885,113
+61,446
+0.6% +$6.15M 1.02% 8
2015
Q1
$1.09B Sell
10,823,667
-11,909
-0.1% -$1.21M 1.05% 5
2014
Q4
$1.13B Sell
10,835,576
-37,617
-0.3% -$3.96M 1.08% 5
2014
Q3
$1.16B Buy
10,873,193
+361,452
+3% +$37.5M 1.15% 5
2014
Q2
$1.1B Sell
10,511,741
-36,586
-0.3% -$3.7M 1.11% 6
2014
Q1
$1.04B Buy
10,548,327
+910,681
+9% +$84.4M 1.11% 6
2013
Q4
$883M Buy
9,637,646
+235,166
+3% +$21.7M 1.01% 9
2013
Q3
$815M Buy
9,402,480
+194,768
+2% +$17.5M 1.01% 7
2013
Q2
$791M Buy
+9,207,712
New +$781M 1.02% 9

Other funds holding JNJ

UBS AM's JNJ Position: Q1 2026 in Review

UBS AM increased its Johnson & Johnson (JNJ) stake by 14% in Q1 2026, buying an estimated $548M and bringing the position to 19,628,113 shares worth $4.8B. The position accounts for 1% of the portfolio, ranked #12.

UBS AM first reported a position in JNJ in Q2 2013 and has held it in 52 quarters since. 4,617 funds tracked by Wall St. Rank hold JNJ as of Q1 2026.

  • UBS AM held 19,628,113 shares of Johnson & Johnson worth $4.8B as of Q1 2026.
  • UBS AM bought 2,352,176 Johnson & Johnson shares in Q1 2026, an estimated $548M.
  • Johnson & Johnson made up 1% of UBS AM's portfolio in Q1 2026, its #12 holding.
  • UBS AM first reported a position in Johnson & Johnson in Q2 2013 and has held it in 52 quarters since.
  • 4,617 funds tracked by Wall St. Rank held Johnson & Johnson as of Q1 2026.

Based on UBS AM's 13F filing for Q1 2026, filed 13 May 2026.